Terms: = Sarcomas AND PDCD1, CD279, PD-1, PD1, SLEB2, hPD-1, hPD-l, hSLE1 AND Clinical Outcome
11 results:
1. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
2. Prognostic impact of the post-treatment T cell composition and spatial organization in soft tissue sarcoma patients treated with neoadjuvant hyperthermic radio(chemo)therapy.
Rupp L; Resag A; Potkrajcic V; Warm V; Wehner R; Jöhrens K; Bösmüller H; Eckert F; Schmitz M
Front Immunol; 2023; 14():1185197. PubMed ID: 37261361
[TBL] [Abstract] [Full Text] [Related]
3. Evaluation of PD-L1 Expression in Undifferentiated Pleomorphic sarcomas, Liposarcomas and Chondrosarcomas.
Zhang Y; Chen Y; Papakonstantinou A; Tsagkozis P; Linder-Stragliotto C; Haglund F
Biomolecules; 2022 Feb; 12(2):. PubMed ID: 35204793
[TBL] [Abstract] [Full Text] [Related]
4. Complement activation promoted by the lectin pathway mediates C3aR-dependent sarcoma progression and immunosuppression.
Magrini E; Di Marco S; Mapelli SN; Perucchini C; Pasqualini F; Donato A; Guevara Lopez ML; Carriero R; Ponzetta A; Colombo P; Cananzi F; Supino D; Reis ES; Peano C; Inforzato A; Jaillon S; Doni A; Lambris JD; Mantovani A; Garlanda C
Nat Cancer; 2021 Feb; 2(2):218-232. PubMed ID: 34505065
[TBL] [Abstract] [Full Text] [Related]
5. CD4+ T cell and M2 macrophage infiltration predict dedifferentiated liposarcoma patient outcomes.
Schroeder BA; LaFranzo NA; LaFleur BJ; Gittelman RM; Vignali M; Zhang S; Flanagan KC; Rytlewski J; Riolobos L; Schulte BC; Kim TS; Chen E; Smythe KS; Wagner MJ; Mantilla JG; Campbell JS; Pierce RH; Jones RL; Cranmer LD; Pollack SM
J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34465597
[TBL] [Abstract] [Full Text] [Related]
6. T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: a clinico-pathological study.
Smolle MA; Herbsthofer L; Granegger B; Goda M; Brcic I; Bergovec M; Scheipl S; Prietl B; Pichler M; Gerger A; Rossmann C; Riedl J; Tomberger M; López-García P; El-Heliebi A; Leithner A; Liegl-Atzwanger B; Szkandera J
Br J Cancer; 2021 Aug; 125(5):717-724. PubMed ID: 34127811
[TBL] [Abstract] [Full Text] [Related]
7. Osteosarcoma and soft-tissue sarcomas with an immune infiltrate express PD-L1: relation to clinical outcome and Th1 pathway activation.
Wunder JS; Lee MJ; Nam J; Lau BY; Dickson BC; Pinnaduwage D; Bull SB; Ferguson PC; Seto A; Gokgoz N; Andrulis IL
Oncoimmunology; 2020 Mar; 9(1):1737385. PubMed ID: 33457085
[TBL] [Abstract] [Full Text] [Related]
8. Telomerase-specific oncolytic immunotherapy for promoting efficacy of pd-1 blockade in osteosarcoma.
Mochizuki Y; Tazawa H; Demiya K; Kure M; Kondo H; Komatsubara T; Sugiu K; Hasei J; Yoshida A; Kunisada T; Urata Y; Kagawa S; Ozaki T; Fujiwara T
Cancer Immunol Immunother; 2021 May; 70(5):1405-1417. PubMed ID: 33151368
[TBL] [Abstract] [Full Text] [Related]
9. A comparative view on the expression patterns of PD-L1 and pd-1 in soft tissue sarcomas.
Orth MF; Buecklein VL; Kampmann E; Subklewe M; Noessner E; Cidre-Aranaz F; Romero-Pérez L; Wehweck FS; Lindner L; Issels R; Kirchner T; Altendorf-Hofmann A; Grünewald TGP; Knösel T
Cancer Immunol Immunother; 2020 Jul; 69(7):1353-1362. PubMed ID: 32222780
[TBL] [Abstract] [Full Text] [Related]
10. Expression of programmed death ligand 1 is associated with poor prognosis in myeloid sarcoma patients.
Kawamoto K; Miyoshi H; Suzuki T; Kiyasu J; Yokoyama S; Sasaki Y; Sone H; Seto M; Takizawa J; Ohshima K
Hematol Oncol; 2018 Aug; 36(3):591-599. PubMed ID: 29602174
[TBL] [Abstract] [Full Text] [Related]
11. Current status of immunotherapy for sarcomas.
Miwa S; Nishida H; Tsuchiya H
Immunotherapy; 2017 Dec; 9(16):1331-1338. PubMed ID: 29185391
[TBL] [Abstract] [Full Text] [Related]
